[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 16 of about 16
2. Swann HM, Holt DE: Canine gastric adenocarcinoma and leiomyosarcoma: a retrospective study of 21 cases (1986-1999) and literature review. J Am Anim Hosp Assoc; 2002 Mar-Apr;38(2):157-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canine gastric adenocarcinoma and leiomyosarcoma: a retrospective study of 21 cases (1986-1999) and literature review.
  • This retrospective study describes the clinical course, treatment, and outcome of 21 dogs with gastric adenocarcinomas (n=19) and leiomyosarcomas (n=2).
  • Medical records from 1986 to 1999 were reviewed for signalment, weight, diagnosis, tumor location, clinical signs, radiographic imaging procedures, surgical procedures, chemotherapy, duration of follow-up monitoring, outcome, cause of death, metastatic rate, metastatic sites, and method of detection of metastasis.
  • Fourteen of 19 (74%) dogs with gastric adenocarcinomas had metastasis.
  • Metastatic sites included gastric lymph nodes, omentum, liver, duodenum, pancreas, spleen, esophagus, adrenal glands, and lungs.
  • Both cases of a gastric leiomyosarcoma had metastatic disease involving the liver (n=2) and duodenum (n=1).
  • Surgery, consisting of either a Billroth I or a gastrojejunostomy, provided immediate relief of the gastric outflow obstruction and clinical improvement in the early postoperative period.
  • The beneficial effects of chemotherapy alone or adjuvant chemotherapy are still unknown.
  • The long-term prognosis for most cases of gastric adenocarcinomas and leiomyosarcomas is poor because of the presence of advanced disease.
  • Surgical resection, however, does alleviate gastric outflow obstruction in the immediate postoperative period.
  • [MeSH-major] Adenocarcinoma / veterinary. Dog Diseases / epidemiology. Leiomyosarcoma / veterinary. Stomach Neoplasms / veterinary
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Dogs. Female. Male. Neoplasm Metastasis. Pennsylvania / epidemiology. Records as Topic / veterinary. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11908834.001).
  • [ISSN] 0587-2871
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 22
  •  go-up   go-down


3. Horenstein MG, Hitchcock TA, Tucker JA: Dual CD117 expression in gastrointestinal stromal tumor (GIST) and paraganglioma of Carney triad: a case report. Int J Surg Pathol; 2005 Jan;13(1):87-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a 36-year-old white woman with complete Carney triad, including metastatic gastric stromal tumor (GIST), pulmonary chondroma, and nonfunctioning extra-adrenal paraganglioma.
  • [MeSH-major] Chondroma / pathology. Gastrointestinal Stromal Tumors / pathology. Leiomyosarcoma / secondary. Lung Neoplasms / pathology. Paraganglioma, Extra-Adrenal / pathology. Proto-Oncogene Proteins c-kit / analysis
  • [MeSH-minor] Adult. Antigens, CD34 / analysis. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Chromogranins / analysis. Drug Therapy. Female. Humans. Palliative Care. Syndrome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735861.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Chromogranins; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


Advertisement
4. Maksimovic S: Double tract reconstruction after total gastrectomy in patients with gastric cancer: our experience. Med Arh; 2010;64(2):116-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double tract reconstruction after total gastrectomy in patients with gastric cancer: our experience.
  • PURPOSE: Gastric cancer (GC) remains one of the most frequent cancers worldwide.
  • The double tract (DT) method is the optimal reconstruction procedure aftertotal gastrectomy for patients with gastric cancer.
  • Tumor diffused in the sections of stomach in 37 cases: cardia and body in 14 cases, body and antrum in 16 cases, and in only body of stomach in 7 cases.
  • In the pathological examination, the tumors of 34 patients were diagnosed as adenocarcinoma, 2 as malignant lymphoma, and i as leiomyosarcoma.
  • CONCLUSIONS: The benefits of this method are (1) a simple procedure;.
  • [MeSH-major] Digestive System Surgical Procedures. Gastrectomy / rehabilitation. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514781.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


5. Li J, Liu P, Wang H, Yu J, Xie P, Liu X: [Clinical analysis of 31 patients with gastric stromal tumors]. Zhonghua Nei Ke Za Zhi; 2002 Nov;41(11):742-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 31 patients with gastric stromal tumors].
  • OBJECTIVE: To investigate the clinical manifestations, diagnosis and treatment of gastric stromal tumors.
  • METHODS: 31 patients with gastric stromal tumors treated from 1993, 1 - 2001, 9 were analyzed retrospectively.
  • The distribution of gastric tromal tumors is fundus > body > antrum.
  • Diagnosis of this condition is sometimes difficult and treatment is often delayed because patients usually present with nonspecific abdominal symptoms.
  • The main manifestations of gastric stromal tumors are upper gastrointestinal hemorrhage 61.3% (19/31), 7 patients with acute hemorrhage and 12 with chronic hemorrhage.
  • Gastroscopy, ultrasound gastroscopy, computed tomography, B type ultrasound and upper gastrointestinal X-ray series are helpful to diagnosis.
  • But the final diagnosis is decided by pathological and immunohistochemistry examinations.
  • Gastric stromal tumors exhibit consistent immunohistochemical expressions of CD(117) and/or CD(34).
  • The operative treatment is thought of the first choice.
  • Effect of the chemotherapy isn't satisfied.
  • There is no standard chemotherapy for gastric stromal tumors.
  • CONCLUSIONS: Gastric stromal tumor is a kind of separated submucosal tumor which is different from leiomyoma, leiomyosarcoma and neurogenic tumors.
  • Pathological and immunohistochemistry inspectations are very important to make clear diagnosis.
  • Early diagnosis and rational treatment are the keys to improve the prognosis.
  • [MeSH-major] Stomach Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12485519.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


6. Donthireddy KR, Ailawadhi S, Nasser E, Schiff MD, Nwogu CE, Nava HR, Javle MM: Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol; 2007 Sep;5(8):355-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant gastroparesis: pathogenesis and management of an underrecognized disorder.
  • Gastroparesis is a disorder of the stomach caused by delayed gastric emptying in the absence of mechanical obstruction.
  • Gastroparesis has been described as a complication of several malignancies, including gastric, pancreatic, gallbladder, esophageal, and lung cancers, as well as leiomyosarcoma.
  • In the setting of malignancy, gastroparesis may result from the cancer itself or may be a complication of its treatment with such modalities as surgery, radiation therapy, or chemotherapy.
  • Appropriate treatment of MG may help to avoid serious consequences, such as cancer cachexia, intolerance of oral anticancer agents, dehydration, and hospitalization.
  • [MeSH-major] Gastric Emptying. Gastrointestinal Agents / therapeutic use. Gastrointestinal Motility / drug effects. Gastroparesis / etiology. Neoplasms / complications
  • [MeSH-minor] Cathartics / therapeutic use. Humans. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Gastroparesis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Support Oncol. 2007 Sep;5(8):368-70 [17944145.001]
  • [CommentIn] J Support Oncol. 2007 Sep;5(8):366-7 [17944144.001]
  • (PMID = 17944143.001).
  • [ISSN] 1544-6794
  • [Journal-full-title] The journal of supportive oncology
  • [ISO-abbreviation] J Support Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cathartics; 0 / Gastrointestinal Agents
  • [Number-of-references] 52
  •  go-up   go-down


8. Vogl TJ, Zangos S, Eichler K, Selby JB, Bauer RW: Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases. Eur Radiol; 2008 Mar;18(3):468-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases.
  • To evaluate repeated hepatic intraarterial chemotherapy (HIC) as a palliative treatment option for unresectable cholangiocarcinoma and liver metastases of various origins that were progressive under systemic chemotherapy.
  • Treated tumor entities were colorectal carcinoma (CRC) (n = 12), breast cancer (BC) (n = 12), cholangiocarcinoma (CCC) (n = 10), pancreatic (n = 4), ovarian (n = 3), gastric, cervical, papillary (each n = 2), prostate, esophageal carcinoma, leiomyosarcoma (each n = 1), cancer of unknown primacy (CUP) (n = 5).
  • All patients tolerated the treatment well without any major side effects or complications.
  • HIC with gemcitabine/mitomycin is a safe, minimally invasive, palliative treatment for hepatic metastases that are progressive under systemic chemotherapy.
  • The treatment yields respectable tumor control rates in CRC and BC patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Palliative Care
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Breast Neoplasms / pathology. Cholangiocarcinoma / pathology. Colorectal Neoplasms / pathology. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Injections, Intra-Arterial. Male. Middle Aged. Mitomycin / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 2:ii93-6 [15958484.001]
  • [Cites] Am J Surg. 2003 Feb;185(2):158-64 [12559448.001]
  • [Cites] Oncology. 2005;69 Suppl 3:17-24 [16301832.001]
  • [Cites] J Natl Cancer Inst. 1988 Mar 16;80(2):84-9 [3278123.001]
  • [Cites] Breast Cancer Res Treat. 2000 Feb;59(3):271-8 [10832597.001]
  • [Cites] Eur J Surg Oncol. 2000 Apr;26(3):209-12 [10753531.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23 (22):4888-96 [16009951.001]
  • [Cites] J Vasc Interv Radiol. 2005 Mar;16(3):353-61 [15758131.001]
  • [Cites] Eur Radiol. 2007 Apr;17(4):1025-34 [16944163.001]
  • [Cites] Acta Oncol. 2003;42(4):263-75 [12899497.001]
  • [Cites] Drugs. 1997 Sep;54(3):447-72 [9279506.001]
  • [Cites] Eur J Surg Oncol. 2005 Nov;31(9):932-41 [15979268.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1402-7 [15726542.001]
  • [Cites] Zentralbl Chir. 1995;120(10):786-90 [7502593.001]
  • [Cites] J Surg Oncol. 2005 Aug 1;91(2):97-101 [16028279.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jul;56(1):67-78 [10517344.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1395-403 [16505413.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Nov;132(11):745-55 [16858591.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(1):53-62 [16319993.001]
  • [Cites] Eur J Radiol. 2002 Jan;41(1):42-8 [11750151.001]
  • [Cites] Oncologist. 2004;9(1):43-57 [14755014.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;33 Suppl:S142-4 [8137476.001]
  • [Cites] Ther Umsch. 2006 Apr;63(4):255-61 [16689456.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4881-7 [16009952.001]
  • [Cites] Eur J Surg Oncol. 2006 Nov;32(9):922-7 [16822644.001]
  • [Cites] J Surg Oncol. 1994 Jan;55(1):26-31; discussion 32 [8289448.001]
  • [Cites] Cancer. 1989 Dec 1;64(11):2203-6 [2529960.001]
  • [Cites] Oncology (Williston Park). 1996 Nov;10(11 Suppl):131-5 [8953600.001]
  • [Cites] Recent Results Cancer Res. 1983;86:1-12 [6647987.001]
  • [Cites] Z Gastroenterol. 2006 Jul;44(7):587-98 [16823700.001]
  • [Cites] Jpn J Clin Oncol. 1999 Jan;29(1):23-7 [10073147.001]
  • [Cites] Ann R Coll Surg Engl. 2005 May;87(3):167-70 [15901375.001]
  • [Cites] Zentralbl Chir. 1998;123 Suppl 5:159-61 [10063604.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] Oncologist. 2005;10 Suppl 3:20-9 [16368868.001]
  • [Cites] Cancer Treat Rep. 1980 Jan;64(1):31-40 [6155210.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):977-86 [9849443.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] ANZ J Surg. 2004 Sep;74(9):781-7 [15379811.001]
  • (PMID = 17938935.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 50SG953SK6 / Mitomycin; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


9. Jadvar H, Tatlidil R, Garcia AA, Conti PS: Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol; 2003 Mar;58(3):215-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography.
  • AIM: We retrospectively assessed the use of [(18)F] fluorodeoxyglucose positron emission tomography (FDG PET) in the evaluation of recurrent disease in patients with history of gastric malignancy.
  • MATERIALS AND METHODS: Eighteen patients were referred for FDG PET for evaluation of recurrent gastric cancer.
  • Prior treatments included total (n = 4) or partial gastrectomy (n = 14) followed by chemotherapy alone (n = 7) or combined chemoradiation therapy (n = 2).
  • The interval between the most recent treatment and PET ranged from 3 months to 2 years.
  • RESULTS: PET was concordant with computed tomography (CT) in 12 patients (5 TP, 6 TN, 1 FN).
  • Additional chemotherapy was initiated in these three patients (17% of total) based on PET localization of disease.
  • PET and a gastric anastomosis biopsy were negative in another patient with positive CT.
  • CONCLUSION: FDG PET may be useful in the evaluation of recurrent gastric cancer, and can localize the disease when CT is non-diagnostic.
  • Imaging evaluation with PET may also impact on the clinical management of patients with recurrent gastric cancer.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Fluorodeoxyglucose F18. Leiomyosarcoma / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Stomach Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 The Royal College of Radiologists
  • [ErratumIn] Clin Radiol. 2003 Jul;58(7):570
  • (PMID = 12639527.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


10. Kikuchi H, Konn H, Kamiya K, Baba M, Ohta M, Kondo K, Hiramatsu Y, Yamamoto M, Tanaka T, Sugimura H, Ohashi M, Kanda T, Nakamura S: [Two cases of postoperative recurrence of gastric GIST treated by imatinib]. Gan To Kagaku Ryoho; 2004 Oct;31(10):1569-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of postoperative recurrence of gastric GIST treated by imatinib].
  • Case 1: This 63-year-old Japanese man received a partial gastrectomy for leiomyosarcoma in 1993.
  • Though the response to treatment was SD-PR initially, a CT scan 15 months after initial treatment demonstrated the regrowth of the tumor in his liver.
  • The response to treatment was SD, and continued for 12 months.
  • IM is the treatment of choice for unresectable recurrence of GIST.
  • Both basic and clinical research is necessary to increase the therapeutic efficacy of IM.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrectomy. Gastrointestinal Neoplasms / drug therapy. Leiomyosarcoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Benzamides. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Imatinib Mesylate. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Protein-Tyrosine Kinases / antagonists & inhibitors. Thyroid Neoplasms / secondary

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15508453.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


11. Matsutani T, Onda M, Miyashita M, Hao K, Yokoyama S, Matsuda T, Futami R, Takubo K, Sasajima K: Liver abscesses associated with stromal tumour of the stomach in a young woman. Eur J Gastroenterol Hepatol; 2001 Dec;13(12):1485-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver abscesses associated with stromal tumour of the stomach in a young woman.
  • She was found to have liver abscesses and a gastric submucosal mass by computed tomography and ultrasonography.
  • Gastroscopy and a barium swallow revealed a round submucosal mass with a giant ulceration in the body of the stomach.
  • Cultures of the fluid from a liver abscess and gastric juice yielded alpha-haemolytic streptococci.
  • The tumour was diagnosed as a stromal tumour of the stomach (leiomyosarcoma) in the final histological report.
  • The patient was discharged on postoperative day 17 without receiving adjuvant radio-chemotherapy.
  • This is a rare case of a liver abscess associated with a stromal tumour of the stomach in a young patient.
  • [MeSH-major] Leiomyosarcoma / complications. Liver Abscess / complications. Liver Abscess / microbiology. Stomach Neoplasms / complications
  • [MeSH-minor] Adult. Candida / isolation & purification. Disease-Free Survival. Female. Humans. Micrococcus / isolation & purification. Neisseria / isolation & purification. Streptococcus pyogenes / isolation & purification. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11742198.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Thong-Ngam D, Tangkijvanich P, Mahachai V, Kullavanijaya P: Current status of gastric cancer in Thai patients. J Med Assoc Thai; 2001 Apr;84(4):475-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of gastric cancer in Thai patients.
  • To determine the current status in various aspects of gastric cancer in Thai patients, we retrospectively reviewed the records of 119 patients with histologically proven gastric cancer in King Chulalongkorn Memorial Hospital during the five-year period from 1994 to 1998.
  • Lesion location was lower third in 40.3 per cent, middle third in 31.9 per cent, upper third in 15.1 per cent and entire stomach in 3.4 per cent of patients.
  • Adenocarcinoma was the most common histological finding (91.6%), followed by lymphoma and leiomyosarcoma (3.4% each).
  • Management was surgical treatment in 58.9 per cent (total gastrectomy 14.5%, subtotal gastrectomy 33.3% and palliative bypass surgery in 11.1%).
  • Systemic chemotherapy was the primary modality of therapy in 16.8 per cent and was adjuvant therapy in 18.5 per cent.
  • The median survival time of resectable cases was 1.00+/-0.53 years, significantly longer than that of unresectable cases (0.11+/-0.03 years) (p=0.0025).
  • However, the administration of chemotherapy did not improve the survival rate.
  • It is concluded that, in Thailand, gastric cancer continues to be an important health problem and is generally associated with a poor prognosis.
  • [MeSH-major] Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11460956.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


13. Rogiers X, Brunken C: Surgical management of hepatic metastatic disease. Saudi Med J; 2000 Jun;21(6):519-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radical surgical resection, if possible, is the treatment of choice.
  • Radical resection of metastases from wilms-tumor, carcinoids, carcinoma of the breast, hypernephroma, adrenal tumors, malignant melanoma, leiomyosarcoma and gastric cancer may improve long time survival, however knowledge is too small for giving general directions.
  • Local destructive therapies are only beneficial when a total necrosis of the tumor is reached.
  • Indications for this treatment are quite rare.
  • Both, systemic and local chemotherapy offers only palliation with little influence on long time survival.
  • Adjuvant and neo-adjuvant chemotherapy is applicated under study conditions with encouraging results.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Colorectal Neoplasms / pathology. Europe / epidemiology. Humans. Patient Selection. Proportional Hazards Models. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11508246.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Saudi Arabia
  • [Number-of-references] 17
  •  go-up   go-down


14. Neagu S, Zărnescu NO, Costea R, Stamatoiu A, Badea V, Dumitrescu C, Grădinaru S, Sajin M, Ardeleanu C, Pelmuş M: [Gastric stromal tumors--Clinical and histopathological analysis of four cases]. Chirurgia (Bucur); 2003 Sep-Oct;98(5):443-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric stromal tumors--Clinical and histopathological analysis of four cases].
  • BACKGROUND: The aim of this study is to present our experience concerning a rare form of gastric tumor--gastrointestinal stromal tumor (GIST).
  • METHODOLOGY: We reviewed data of four patients with gastric stromal tumors, which have been admitted in our department from 1998-2002.
  • During surgery we discovered proximal gastric tumors with 4, 5, 10 and 20 cm in largest diameter.
  • We performed excision of the whole tumor with a security limit of 2 cm or gastric resection (one case), without limphadenectomy.
  • One patient developed an anastomotic fistula with a good evolution under conservative treatment.
  • Histopathological and immunohistochemical study diagnosed gastric stromal tumors by identifying the CD 117 maker.
  • Postoperatively neither one of our patients received chemotherapy or radiotherapy.
  • The other two patients are in a good condition up to date, without metastasis, one and respectively three years after surgical treatment.
  • CONCLUSIOUS: Correct diagnosis, complete tumor resection and surveillance are essential steps in management of gastric stromal tumors.
  • [MeSH-major] Leiomyosarcoma / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Male. Middle Aged. Proto-Oncogene Proteins c-kit / analysis. Retrospective Studies. Stromal Cells / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14999973.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


15. Pérez-Gutiérrez S, González-Cámpora R, Amérigo-Navarro J, Beato-Moreno A, Sánchez-León M, Pareja Megía JM, Virizuela-Echaburu JA, López-Beltrán A: Expression of P-glycoprotein and metallothionein in gastrointestinal stromal tumor and leiomyosarcomas. Clinical implications. Pathol Oncol Res; 2007;13(3):203-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • P-GP expression was unrelated to anatomic location (gastric vs. intestinal) in GIST (39/45 vs. 35/43, p=0.770) and in GI-LMS (0/2 vs. 2/6, p=1.000).
  • MT expression was unrelated to the anatomic location (gastric vs. intestinal) in GIST (7/45 vs. 6/43) and GI-LMS (0/2 vs. 1/6) (p=1.000 and p=0.1000, respectively).
  • Differential expression of P-GP and MT might explain the known variability in response to systemic chemotherapy in these tumors.
  • Detection of P-GP and MT seems to add certain prognostic value in GIST (MT) or GI-LMS (P-GP).
  • [MeSH-major] Gastrointestinal Neoplasms / metabolism. Gastrointestinal Stromal Tumors / metabolism. Leiomyosarcoma / metabolism. Metallothionein / metabolism. P-Glycoprotein / metabolism
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2001 Jun;32(6):578-82 [11431711.001]
  • [Cites] Curr Drug Deliv. 2004 Jul;1(3):203-12 [16305384.001]
  • [Cites] Ann Chir Gynaecol. 1998;87(4):297-305 [9891770.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Leuk Lymphoma. 2001 May;41(5-6):513-22 [11378569.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2918-26 [6850603.001]
  • [Cites] Biochim Biophys Acta. 2002 Jul 18;1587(2-3):318-25 [12084474.001]
  • [Cites] Cancer Invest. 2002;20(5-6):605-12 [12197215.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Virchows Arch. 2003 Jun;442(6):529-37 [12743815.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] J Natl Cancer Inst. 1990 Oct 3;82(19):1553-61 [1976136.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7593-8 [16278376.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3211-20 [10986053.001]
  • [Cites] Histol Histopathol. 2005 Jan;20(1):83-9 [15578426.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):821-9 [15648083.001]
  • [Cites] Pathol Int. 2006 Jan;56(1):1-9 [16398673.001]
  • [Cites] Methods Enzymol. 1991;205:613-26 [1779825.001]
  • (PMID = 17922049.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / P-Glycoprotein; 9038-94-2 / Metallothionein
  •  go-up   go-down


16. Théou N, Gil S, Devocelle A, Julié C, Lavergne-Slove A, Beauchet A, Callard P, Farinotti R, Le Cesne A, Lemoine A, Faivre-Bonhomme L, Emile JF: Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib. Clin Cancer Res; 2005 Nov 01;11(21):7593-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract and respond poorly to chemotherapy.
  • A tyrosine kinase inhibitor treatment, imatinib mesylate, was recently shown to have antitumor effects in metastatic patients.
  • However, this drug is a substrate for multidrug resistance (MDR) proteins.
  • ABCB1 was expressed in all gastric GISTs, but in only 67% of nongastric GISTs.
  • The levels of these MDR proteins in gastric GISTs were higher for ABCB1 (P = 0.007) and lower for ABCC1 (P = 0.004) compared with nongastric GISTs.
  • These results confirm that gastric and nongastric GISTs have different biological characteristics and suggest that MDR proteins do not impair the initial response of the tumor to imatinib.
  • [MeSH-major] Drug Resistance, Multiple. Drug Resistance, Neoplasm. Gastrointestinal Neoplasms / drug therapy. Gene Expression Regulation, Neoplastic. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family G, Member 2. ATP-Binding Cassette Transporters / biosynthesis. ATP-Binding Cassette, Sub-Family B, Member 1 / biosynthesis. Adult. Aged. Antineoplastic Agents / pharmacology. Benzamides. Blotting, Western. Enzyme Inhibitors / therapeutic use. Female. Humans. Imatinib Mesylate. Immunohistochemistry. Leiomyosarcoma / metabolism. Male. Middle Aged. Multidrug Resistance-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis. Protein Kinase Inhibitors / pharmacology. Protein-Tyrosine Kinases / antagonists & inhibitors. Risk

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16278376.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Enzyme Inhibitors; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; Y49M64GZ4Q / multidrug resistance-associated protein 1
  •  go-up   go-down






Advertisement